Abstract：
Purpose: Ozurdex had shown promising anatomical and functional outcomes in managing refractory Irvine-Gass syndrome over the years. Burgeoning usage of Ozurdex has prompted the study of its related complications, particularly the anterior chamber migration of the implant. Methods: Literature reviews on the anterior chamber migration of the Ozurdex via PubMed, EBSCO, and TRIP databases were searched from 2012 to 2020. The predisposing factors, outcomes, and management of such cases were evaluated. Results: A total of 54 articles consisting of 105 cases of anterior migration of Ozurdex were included in this analysis. The vitrectomized eye and compromised posterior capsule were highly associated with this complication. About 81.9% of the cases had cornea edema upon presentation, with 31.4% of them ending up with cornea decompensation despite intervention. Although there was high intraocular pressure reported initially in 22 cases, only 2 cases required glaucoma filtration surgeries in which they had preexisting glaucoma. Numerous techniques of repositioning or surgical removal of the implant were described but they were challenging and the outcomes varied. Conclusions: A noninvasive method of manipulating the Ozurdex into the vitreous cavity via the \"Trendelenburg position, external pressure with head positioning\" maneuvers is safe yet achieves a favorable outcome. Precaution must be taken whenever offering Ozurdex to the high-risk eyes. Prompt repositioning or removal of the implant is crucial to deter cornea decompensation. Clinical Trial Registration number: NMRR-22-02092-S9X (from the Medical Research and Ethics Committee (MREC), Ministry of Health, Malaysia).
摘要：
目的：多年来，Ozurdex在治疗难治性Irvine-Gass综合征方面显示出有希望的解剖学和功能结果。Ozurdex的新兴使用促使了对其相关并发症的研究，特别是植入物的前房迁移。方法：通过PubMed对Ozurdex前房迁移的文献综述，EBSCO,和TRIP数据库从2012年到2020年进行了搜索。诱发因素,结果，并对此类病例的管理进行了评估。结果：本分析共纳入54篇文献，包括105例Ozurdex前迁移病例。玻璃体切除的眼睛和受损的后囊与该并发症高度相关。约81.9%的病例出现角膜水肿，尽管进行了干预，但其中31.4％的患者最终会出现角膜代偿失调。尽管最初有22例报告有高眼压，只有2例患者需要青光眼滤过手术，其中他们已经存在青光眼。描述了许多重新定位或手术切除植入物的技术，但它们具有挑战性，结果各不相同。结论：通过Trendelenburg位置操纵Ozurdex进入玻璃体腔的非侵入性方法，头部定位的外部压力“机动是安全的，但取得了良好的结果。每当向高风险的眼睛提供Ozurdex时，都必须采取预防措施。及时重新定位或移除植入物对于阻止角膜代偿失调至关重要。临床试验注册号：NMRR-22-02092-S9X（来自医学研究与伦理委员会（MREC），卫生部,马来西亚）。
